These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38228892)

  • 21. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
    Rodriguez-Vieitez E; Kumar A; Malarte ML; Ioannou K; Rocha FM; Chiotis K
    Methods Mol Biol; 2024; 2785():195-218. PubMed ID: 38427196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
    Nilsson J; Pichet Binette A; Palmqvist S; Brum WS; Janelidze S; Ashton NJ; Spotorno N; Stomrud E; Gobom J; Zetterberg H; Brinkmalm A; Blennow K; Hansson O
    Brain; 2024 Jul; 147(7):2414-2427. PubMed ID: 38325331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease.
    Pereira JB; Janelidze S; Ossenkoppele R; Kvartsberg H; Brinkmalm A; Mattsson-Carlgren N; Stomrud E; Smith R; Zetterberg H; Blennow K; Hansson O
    Brain; 2021 Feb; 144(1):310-324. PubMed ID: 33279949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An
    Li J; Huang Q; Qi N; He K; Li S; Huang L; Pan F; Ren S; Hua F; Huang Y; Guan Y; Guo Q; Zhao J; Xie F
    J Cereb Blood Flow Metab; 2024 Jul; 44(7):1199-1207. PubMed ID: 38295871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.
    Dhiman K; Blennow K; Zetterberg H; Martins RN; Gupta VB
    Cell Mol Life Sci; 2019 May; 76(10):1833-1863. PubMed ID: 30770953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [
    Sanabria Bohórquez S; Marik J; Ogasawara A; Tinianow JN; Gill HS; Barret O; Tamagnan G; Alagille D; Ayalon G; Manser P; Bengtsson T; Ward M; Williams SP; Kerchner GA; Seibyl JP; Marek K; Weimer RM
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2077-2089. PubMed ID: 31254035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease.
    Oeckl P; Janelidze S; Halbgebauer S; Stomrud E; Palmqvist S; Otto M; Hansson O
    Alzheimers Dement; 2023 Nov; 19(11):5095-5102. PubMed ID: 37186338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
    Fleisher AS; Pontecorvo MJ; Devous MD; Lu M; Arora AK; Truocchio SP; Aldea P; Flitter M; Locascio T; Devine M; Siderowf A; Beach TG; Montine TJ; Serrano GE; Curtis C; Perrin A; Salloway S; Daniel M; Wellman C; Joshi AD; Irwin DJ; Lowe VJ; Seeley WW; Ikonomovic MD; Masdeu JC; Kennedy I; Harris T; Navitsky M; Southekal S; Mintun MA;
    JAMA Neurol; 2020 Jul; 77(7):829-839. PubMed ID: 32338734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
    Takahashi RH; Nagao T; Gouras GK
    Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
    Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
    J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease.
    Horie K; Li Y; Barthélemy NR; Gordon B; Hassenstab J; Benzinger TLS; Fagan AM; Morris JC; Karch CM; Xiong C; Allegri R; Mendez PC; Ikeuchi T; Kasuga K; Noble J; Farlow M; Chhatwal J; Day G; Schofield PR; Masters CL; Levin J; Jucker M; Lee JH; Roh JH; Sato C; Sachdev P; Koyama A; Reyderman L; Bateman RJ; McDade E;
    Ann Neurol; 2023 Jun; 93(6):1158-1172. PubMed ID: 36843330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
    Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.